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Human beings suﬀer from two diﬀerent kinds of ﬁbrillations: one is atrial ﬁbrillation (AF)
and the other is ventricular ﬁbrillation (VF). AF is the most common sustained arrhythmia and
VF is the most serious. Pharmacological cardioversion with conventional class I antiar-
rhythmic drugs is usually little help in terminating long-lasting AF. However, bepridil, a
multi-channel blocker, alone or in combination with aprindine restored the sinus rhythm in
about 70% of patients. The average time to conversion was one month, and cardioversion was
associated with a signiﬁcant increase in ﬁbrillation cycle length. After cardioversion, atrial
contraction recovered within one week, and sinus rhythm was maintained better than after
conventional electrical cardioversion. Pharmacological cardioversion of long-lasting AF with
bepridil could become a new therapeutic option targeting remodeled atria. Patients with
idiopathic VF have a characteristic J wave and ST elevation along with a lower QT-RR slope
and short QT interval at slower heart rates. Although an implantable cardioverter deﬁbrillator
(ICD) is the most reliable therapy for idiopathic VF, both bepridil and disopyramide
normalized repolarization dynamics (slope of the QT-RR relationship) and reduced the
frequency of spontaneous VF episodes and ICD shocks. Pharmacological therapy for
cardioversion of persistent AF and prevention of idiopathic VF may play a key role in
improving not only quantity but also quality of life.
(J Arrhythmia 2007; 23: 102–114)
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Introduction
Cardiac ﬁbrillations can be divided into two types:
one is atrial ﬁbrillation (AF), and the other is
ventricular ﬁbrillation (VF). VF is the most serious
arrhythmia and directly threatens survival, while AF
is the most common sustained arrhythmia and
mainly aﬀects quality of life. Both electrical therapy
and pharmacological therapy play important roles
for the treatment of ﬁbrillations. This review focuses
on termination of long-lasting AF and prevention of
idiopathic VF using antiarrhythmic drugs. Interest-
ingly, bepridil hydrochloride, a multi-channel block-
er, is eﬀective for the treatment of both ﬁbrillations.
Pharmacological Therapy for AF
Conversion of long-lasting AF to sinus rhythm
with antiarrhythmic drugs
Pharmacological cardioversion is eﬀective for
termination of AF lasting only a few days, but is
of little help for termination of long-lasting persis-
tent AF.1) Amiodarone is the exception and has some
eﬃcacy for conversion of persistent AF to sinus
rhythm.2) Long-lasting AF induces changes in ion
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channel properties, such as decreasing protein levels
of the L-type Ca channel and several K channels
(Kv4.3, Kv1.5, HERG, minK, and Kir3.1), that make
pharmacological conversion more diﬃcult in persis-
tent AF than in paroxysmal AF.3,4) In a canine model
of AF with atrial tachypacing, amiodarone was
shown to prevent down-regulation of the L-type
Ca channel and reversed pacing-induced shortening
of atrial refractoriness.5) However, clinical use of
amiodarone is limited because of its extracardiac
side eﬀects.
Bepridil is a multi-channel blocker like amiodar-
one, and has both anti-anginal and anti-arrhythmic
eﬀects. Several reports have demonstrated that
bepridil inhibits both L- and T-type Ca currents as
well as Na current in isolated cardiac myocytes.6,7)
Bepridil also inhibits several K currents including
slow, rapid, and ultra-rapid components of delayed
rectiﬁer K current, muscarinic acetylcholine recep-
tor-operated K current, and ATP-sensitive K cur-
rent.8–11) Bepridil prolongs atrial action potential
duration and is expected to be eﬀective for con-
version of AF.9) The K channel blocking actions are,
however, supposed to increase risks for prolongation
of the QT interval and torsades de pointes.8)
Perelman et al. demonstrated that bepridil was
more eﬀective than amiodarone in terminating
established AF (3 months) but was also associated
with life-threatening ventricular arrhythmias.12) They
concluded that arrhythmogenic actions of bepridil
make it unsuitable for treatment of AF. However,
they administered bepridil at dosages of 200 to 600
mg/day, which are extremely high compared with
those employed in Japan (100–200mg/day).
To minimize the adverse eﬀects of bepridil
without losing its eﬃcacy, a combination therapy
with bepridil and aprindine was chosen.13) Aprindine
was selected because of its unique Na channel
blocking properties.14) As a class Ib antiarrhythmic
drug similar to lidocaine, aprindine may counter-
balance excessive QT prolongation induced by
bepridil. Aprindine blocks the Na channel mainly
in the inactivated state; therefore prolongation of the
action potential duration by bepridil would enhance
the Na channel-blocking eﬀect of aprindine on the
atrial cells. In addition to its class I antiarrhythmic
drug action, aprindine causes a moderate reduction
of delayed rectiﬁer K current and hyperpolarization-
activated inward current.15)
Efﬁcacy and safety of bepridil alone or in com-
bination with aprindine for cardioversion of long-
lasting AF
The study group consisted of 32 consecutive
patients (23 men, mean age of 61 8 years) with AF
lasting 3 months without a history of sinus node
dysfunction.13) Patients received bepridil (200mg/
day) for 4 weeks after anticoagulation therapy with
warfarin. If sinus rhythm was not restored with
bepridil and QT interval prolongation was not
excessive (QTc <0:50 sec and %increase <25% of
the baseline value), oral aprindine (40 or 60mg/day)
was added to bepridil (Figure 1). Fast Fourier trans-
form analysis (20 consecutive 4096-msec epochs
with 50% overlap) was performed using lead V1
before and after bepridil administration. The ﬁbril-
lation cycle length (FCL) was calculated from the
peak frequency of each epoch.
Representative electrocardiograms and spectral
analyses from a patient with pharmacological con-
version by a combination of bepridil with aprindine
are shown in Figure 2. In 10 of 32 patients, oral
bepridil converted AF to sinus rhythm an average
of 19 days (7–28 days) after bepridil was started
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Figure 1 Outcome of pharmaco-
logical conversion of long-lasting AF
(from reference 13).
Numbers at the bottom of each box
indicate the number of patients. The
ﬁnal success rate of conversion with
bepridil alone or in combination with
aprindine was 69% (22 of 32 patients).
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(phase I) (Figure 1). Sixteen of 22 patients who
initially failed to respond to bepridil received oral
aprindine in addition to bepridil. In 11 of the 16
patients, AF was terminated an average of 11 days
(4–21 days) after aprindine was added to bepridil
(phase II). Six patients who had failed to respond
to bepridil were followed without administration of
aprindine. Only one of them recovered sinus rhythm
during phase II. The ﬁnal rate of conversion with
bepridil alone or in combination with aprindine
was 69%, and the time to conversion after starting
bepridil was 30 12 days. The duration of AF was
signiﬁcantly shorter in responders than in non-
responders. Responders had a greater increase in
FCL due to bepridil than non-responders (Figure 2).
The increase in the QTc interval with bepridil, left
ventricular ejection fraction, and left atrial dimen-
sion did not diﬀer between the two groups.
No adverse eﬀects necessitating drug discontinu-
ation occurred. However, bepridil dosage was
reduced from 200mg to 100mg/day in 7 patients
because of excessive QT prolongation and sinus
bradycardia.
Frequency analysis of ﬁbrillation waves
During AF, precise manual measurements of
ﬁbrillation intervals are practically diﬃcult and
inaccurate. Several investigators analyzed frequency
characteristics of ﬁbrillation waves from surface
ECG using QRST subtraction methods and demon-
strated that spectral analysis of surface ECG in AF
is useful for quantiﬁcation of ﬁbrillation wave
characteristics.16,17) In our previous study, the mean
FCL obtained from intracardiac electrograms at the
right atrial free wall was a good predictor of AF
termination with class I antiarrhythmic drugs,18)
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Figure 2 ECGs and spectral analyses of ﬁbrillation waves in a representative patient with conversion of atrial ﬁbrillation (AF)
by bepridil and aprindine.
This 61-year-old male had persistent AF lasting 36 months preceded by drug-resistant paroxysmal AF (18 months). He had apical type of
hypertrophic cardiomyopathy and enlarged left atrium (48mm). Before bepridil administration, QTc was 0.44 and ﬁne ﬁbrillation waves
were observed in V1. After a combination of bepridil and aprindine, QTc was 0.43, and ﬁbrillation waves became coarser in V1. Sinus
rhythm was restored 30 days after starting bepridil therapy. During sinus rhythm, QTc was 0.44. Mean ﬁbrillation cycle length (FCL)
calculated from the peak frequency was 141 msec before bepridil (lower left), and it increased to 207 msec after bepridil and aprindine
therapy (lower right). The peak frequency shifted to the left after a combination of bepridil and aprindine was started.
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similar to termination of AF with bepridil alone or in
combination with aprindine.13)
Spectral analysis was performed not only to
measure FCL but also to quantify AF organization.19)
The ratio of the spectral zone with the maximum
power to the total spectral area between 3 to 12Hz
was calculated from power spectral analysis of each
epoch (Figure 3). The area ratio, which may represent
the degree of AF organization, was termed the
ﬁbrillation organization index (FOI). FCL consists
of a refractory period and a temporal excitable gap.
On the other hand, the FOI is related to the size of
the reentry circuit (pathway length), consisting of
a wavelength and an spatial excitable gap. Power
spectra showing multiple peaks and lower FOI may
represent a greater number of circulating wavelets in
the atria as compared with those with a single-peak
pattern. Everett et al. quantiﬁed AF organization
using spectral analysis in a canine AF model.20) They
demonstrated that the deﬁbrillation energy of AF
was dependent on the degree of AF organization:
higher deﬁbrillation energy was required for termi-
nation of AF with less organized ﬁbrillation waves.
According to the multiple wavelets hypothesis, the
number of wavelets varies as a result of variation
in the rate of wavelet formation and extinction.21)
Drugs decreasing the number of wavelets may
increase the FOI and thereby increase the propensity
for AF termination.
Serial changes of FCL and FOI were analyzed
before and after bepridil administration. A critical
increase in not only FCL but also FOI was required
for termination of long-lasting persistent AF with
bepridil alone or in combination with aprindine
(Figure 4).19) The increase in FCL and FOI by
bepridil alone may be attributable mainly to a
class III action that increases atrial refractoriness,
and a combination with aprindine may cause
conduction delay at pivot points of functional reentry
that increases FCL further.22) These eﬀects may lead
to prolongation of FCL with fewer organized wave-
lets and increase the possibility of eliminating all
circulating wavelets simultaneously. In patients
who are scheduled for termination of persistent AF,
evaluation of FCL and FOI after drug administration
is expected to be a useful predictor of success for
pharmacological cardioversion.
Recovery of atrial mechanical function after
pharmacological restoration of sinus rhythm
The electrical remodeling is reversible within a
few days after restoration of sinus rhythm.23) In
contrast, recovery from mechanical stunning re-
quires a longer time than recovery from electrical
remodeling, depending on the duration of AF.24)
Manning et al. reported that atrial mechanical
recovery was achieved within one week in patients
with AF of moderate duration (2–6 weeks) and
within one month in patients with AF of longer
duration (>6 weeks).24) Nishino et al. demonstrated
that atrial mechanical function showed no change
over the ﬁrst week and improved between one and
four weeks after conversion in patients with longer
duration of AF (>6 months).25)
FOI=65%
Peak Frequency 8.3 Hz FCL=120 ms
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0
1500
mV2
Figure 3 Power spectral analysis of ﬁbrillation waves (from reference 19).
Fibrillation cycle length (FCL) was calculated from the peak frequency with the maximum magnitude from each
epoch. The ﬁbrillation organization index (FOI) was derived from the area ratio of the spectral zone with the
maximum power to the total spectral area from 3 to 12Hz from each epoch.
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Compared with these reports, pharmacological
cardioversion with bepridil or in combination with
aprindine signiﬁcantly enhanced the recovery of
atrial mechanical function.26) As shown in Figure 5
(the same patient as in Figure 2), signiﬁcant atrial
contractile ﬂow across the mitral valve was observed
seven hours after pharmacological cardioversion
with bepridil. After pharmacological cardioversion
of long-lasting AF with bepridil, atrial contraction
recovered faster, within one week, and did not
change further from the ﬁrst week in the ﬁrst
month.26) Pharmacological conversion with bepridil
may be beneﬁcial to prevent the occurrence of
thromboembolic events, because left atrial mechan-
ical dysfunction after cardioversion is implicated in
the development of thromboembolic stroke.
Post-cardioversion atrial stunning in humans seems
to be the result of a functional loss of contraction due
to reduction of L-type Ca current.27) Findings from a
canine model of chronic rapid atrial pacing suggested
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Figure 4 Relationship between ﬁ-
brillation cycle length (FCL) and
ﬁbrillation organization index (FOI)
with respect to pharmacological car-
dioversion of atrial ﬁbrillation (AF)
(from reference 19).
Values of FCL and FOI included both
before ( ) and after ( , ) drug
administration. Conversion of AF ( )
occurred in 100% patients with both
FCL 190 msec and FOI 45% and in
0% of those with both FCL <190msec
and FOI <45%. In patients with either
a combination of FCL 190 msec and
FOI <45% or a combination of FCL
<190msec and FOI 45%, 9 of 16
(56%) persistent AF converted pharma-
cologically.
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Figure 5 Atrial mechanical function after pharmacological cardioversion evaluated by pulsed-
Doppler echocardiography (the same patient as in Figure 2).
Left panel: The peak velocity of the A wave was 32 cm/sec seven hours after pharmacological conversion.
Right Panel: The peak velocity of the A wave was 38 cm/sec two days after pharmacological conversion.
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that not only a reduced systolic Ca transient but also
impaired cellular Ca handling may contribute to atrial
contractile dysfunction.28) Both bepridil and amio-
darone have a T-type Ca channel blocking action
similar to mibefradil, which attenuates atrial tachy-
cardia-induced electrical remodeling.29) This T-type
Ca channel blocking action may play a role in
recovery of not only electrical remodeling but also
post-cardioversion atrial stunning. In cultured rat
ventricular myocytes, bepridil increased the Ca sen-
sitivity of contractile proteins and oﬀset the negative
inotropic eﬀect of the L-type Ca channel blocking
action.30) This Ca-sensitizing eﬀect may also con-
tribute to the early recovery of atrial mechanical
function after restoration of sinus rhythm.
Maintenance of sinus rhythm after pharmacolog-
ical cardioversion of persistent AF
Human AF is associated with marked shortening
of the action potential duration and FCL as the
electrical remodeling progresses.31) A shortened FCL
induced by persistent AF favors further perpetuation
of AF. Pharmacological termination of long-lasting
AF with bepridil alone or in combination with
aprindine was preceded by an increase in FCL and
FOI. The increase in FCL due to bepridil is in some
part attributable to direct eﬀects on several ion
channels, but the time course of bepridil action
(gradual increase in FCL and long pharmacological
conversion interval) suggests the contribution of an
additional eﬀect on channel protein expression (anti-
remodeling action).32) Amiodarone is also eﬀective
for pharmacological cardioversion of persistent AF
and increases the eﬃcacy of electrical cardioversion
because it may reverse already established atrial
remodeling.5) The delay in pharmacological cardio-
version due to amiodarone (one month) is attrib-
uted in part to this reversal of remodeling.
As shown in Figure 6, sinus rhythm was main-
tained better in patients with pharmacological car-
dioversion with bepridil (80% at 12 months) than
in patients with electrical cardioversion (40% at 12
months).26) After successful pharmacological cardi-
oversion, some patients may have recurrences of
paroxysmal AF, but they could terminate sponta-
neously. On the other hand, electrical cardioversion
terminates AF suddenly without aﬀecting the re-
modeled AF substrate. Consequently, if AF recurs
shortly after electrical cardioversion, it may not
terminate spontaneously. These diﬀerences in the
atrial substrate after sinus restoration may contribute
to the lower recurrence rate of persistent AF in
patients with pharmacological cardioversion with
bepridil compared with electrical cardioversion.
Persistent AF with and without a history of drug
refractory paroxysmal AF
AF usually starts as paroxysmal type and is
transformed into persistent type.33,34) The mecha-
nisms of paroxysmal AF consist mainly of initiating
factors, and the role of maintaining factors is less
important. The role of maintaining factors becomes
more important in association with the progression
of AF.35)
In our study, approximately one third of persistent
AF had been preceded by drug-refractory paroxys-
mal AF.36) This type of persistent AF may have both
initiating and maintaining factors. The remaining
two thirds of patients with persistent AF did not have
any history of paroxysmal AF as a prelude. This type
of persistent AF depends mainly on maintaining
factors caused by structural remodeling.
Although FCL after bepridil therapy was signiﬁ-
cantly shorter in patients with a history of parox-
ysmal AF than in those without,36) their conversion
rates did not diﬀer. Bepridil therapy for pharmaco-
logical conversion of persistent AF could become
an additional therapeutic option irrespective of the
history of drug-resistant paroxysmal AF.
Combination of inhibitors of renin-angiotensin
system with bepridil
In the clinical setting, angiotensin-converting
enzyme inhibitors can reduce the prevalence of AF
in patients with congestive heart failure (CHF) or
left ventricular dysfunction after myocardial infarc-
tion.37,38) In a canine CHF model of AF, enalapril
0 100 200 300 400
1.0
0.8
0.6
0.4
0.2
0
Pharmacological Conversion
Electrical Conversion
P<0.005
Days after Cardioversion
Pr
ob
ab
ilit
y 
of
 R
em
ai
ni
ng
 
in
 S
in
u
s 
R
hy
th
m
Figure 6 Kaplan-Meier curves for probability of remaining
in sinus rhythm after pharmacological conversion and elec-
trical conversion (from reference 26).
At the 12-month follow-up examination, 83% of the 22 patients
who had been converted to sinus rhythm pharmacologically using
bepridil were free of recurrence of persistent AF, as compared
with 36% of the 16 patients who had been converted electrically
without bepridil administration.
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attenuated changes in tissue angiotensin II and atrial
ﬁbrosis and reduced AF duration.39) In our previous
study, enalapril did not suppress shortening of the
atrial refractoriness induced by long-term rapid atrial
pacing but suppressed both atrial interstitial ﬁbrosis
and increased expression of connexin43 and perpet-
uation of AF without improving left ventricular
function.40) Enalapril also prevented sinus node
dysfunction induced by rapid atrial pacing, possibly
through suppression of interstitial ﬁbrosis and apop-
tosis in the sinus node.41) These observations suggest
that combined administration of inhibitors of the
renin-angiotensin system may be useful to preserve
sinus node function after restoration of sinus rhythm
with bepridil.
Pharmacological Therapy for VF
Repolarization dynamics in idiopathic VF pa-
tients
Idiopathic VF has been recognized as a cause of
unexplained sudden nocturnal death in middle-aged
men, especially in Asian countries.42,43) In some of
these patients with idiopathic VF, a high-takeoﬀ ST
segment and prominent J wave in the right precordial
leads have been reported as Brugada syndrome.44)
Idiopathic VF patients without this speciﬁc ECG
pattern have also been reported, and some of them
have a prominent J wave in the inferior leads
(Figure 7).45,46) In our previous study, we analyzed
Holter ECGs recorded just after VF episodes and
found that idiopathic VF patients had lower QT-RR
slopes and impaired prolongation of the QT interval
at longer RR intervals compared with control healthy
subjects (Figure 8).46) These repolarization character-
istics in idiopathic VF patients during sinus brady-
cardia may be related to the nocturnal occurrence of
VF episodes.
Mechanism of short QT interval at slower heart
rates in idiopathic VF
Several studies suggested that the presence of a
prominent transient outward current (Ito) in the right
ventricular epicardial layer and genetic abnormal-
ities of the sodium channel gene (SCN5A) may play
a key role in the characteristic ECG pattern in
Brugada syndrome.47,48) Experiments using wedge
preparations of canine heart revealed that a down-
sloping ST segment elevation may be caused by an
earlier repolarization of the epicardial action poten-
tial due to a more intense Ito.47) Na channel blocking
agents induced a coved type of ST elevation in the
precordial leads49) because they accentuated the Ito-
mediated notch and failed to develop the action
potential plateau (loss of dome). In a canine in vivo
model of Brugada syndrome, epicardial cooling at
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Figure 7 Twelve-lead ECG and monitor
ECG recordings at the onset of ventricular
ﬁbrillation from a patient with J waves in the
inferior leads (from reference 46).
ST segment elevation and J waves were seen in
the inferior leads, and no speciﬁc ST segment
elevation in the precordial leads was seen.
Before ventricular ﬁbrillation, short-coupled
ventricular bigeminy and prominent J waves
were seen (CM5 lead).
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the right ventricular outﬂow tract induced J point
elevation and T wave inversion in the right pre-
cordial leads and enhanced ventricular vulnerability
(Figure 9).50) Myocardial cooling increased Ito and
slowed Ca channel activation, and vagal nerve stimu-
lation increased these cooling-induced changes. In
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Figure 8 QT-RR and QaT-RR re-
lationships and representative Holter
ECG recordings in a patient with J
waves in the inferior leads (from
reference 46).
Slopes of the QT-RR and QaT-RR
regression lines were low. QT at RR
of 0.66 second was 0.32 second and QT
at RR of 1.32 seconds was 0.36 second.
This is the same patient as shown in
Figure 7.
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Figure 9 Induction of ventricular ﬁbrillation in a canine in vivo model of Brugada syndrome
(from reference 50).
A: Cooling-induced J point elevation and T wave inversion (arrows) disappeared after isoproterenol
administration. B: Ventricular ﬁbrillation was induced by addition of vagal nerve stimulation (VNS)
during cooling and isoproterenol administration without extrastimulation.
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patients with Brugada syndrome, vagal nerve activity
evaluated by heart rate variability indices correlated
with the degree of ST segment elevation.51)
We speculate that these abnormalities of ionic
currents aﬀect not only conﬁguration of the ST
segment pattern but also ventricular repolarization
dynamics. Either reduction of inward currents or
augmentation of outward currents causes early
repolarization, resulting in shortening of the QT
interval. At rest, an increase in Ito may limit the
excessive prolongation of action potential duration,
especially at slower heart rates, and also produce a J
wave in surface ECG. During exercise, both faster
heart rates and an increase in adrenergic tone may
oﬀset the excessive Ito current52) and make a
diﬀerence in QT interval at higher heart rates
insigniﬁcant compared with healthy subjects.
Pharmacological therapy for prevention of idio-
pathic VF
In idiopathic VF patients, the most reliable
therapy for prevention of sudden death is implanta-
tion of implantable cardioverter deﬁbrillator (ICD).
However, frequent episodes of VF reduce the quality
of life because of frequent shock therapy from the
ICD. Belhassen et al. reported that quinidine is
eﬀective for prevention of spontaneous episodes of
VF in Brugada syndrome, but it was associated with
a 36% incidence of side eﬀects.53)
Bepridil has unique electrophysiological abilities
to inhibit outward currents, including most types of
K current and Ito, along with weak inhibitory eﬀect
on inward Na current. Disopyramide possesses
intermediate kinetics of the Na channel blocking
eﬀect and suppresses several types of K current
(rapid component of delayed rectiﬁer K current,
muscarinic acetylcholine receptor-operated K cur-
rent, and ATP-sensitive K current) and Ito.54) Both
drugs prolong the QT interval signiﬁcantly and seem
to be eﬀective for idiopathic VF patients.
Effects of bepridil and disopyramide on idiopathic
VF
The study group consisted of 8 men (age 43:6
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Figure 10 Twelve-lead electrocardiogram in a patient with Brugada syndrome before and after pharmacological therapy with
bepridil (from reference 55).
Before drug therapy (control), saddleback-type ST segment elevation was seen in V2, and the QT interval in V5 was 0.34 sec. After
bepridil (200mg/day) administration for 12 months, the QT interval increased to 0.40 sec and J wave elevation in V2 was suppressed.
(Case 4 in Table 1)
J Arrhythmia Vol 23 No 2 2007
110
9:1 years) with idiopathic VF (Brugada type 5
patients, prominent J wave in the inferior leads 3
patients) who had documented spontaneous episodes
of VF, 7 of whom had ICD.55) The relationship
between QT and RR intervals was analyzed by 24-
hour Holter ECG using an automatic analyzing
system before and after pharmacological therapy
(bepridil 5 and disopyramide 3). From QT-RR linear
regression lines, QT intervals were determined at RR
intervals of 0.6 sec [QT(0.6)], 1.0 sec [QT(1.0)], and
1.2 sec [QT(1.2)].
Bepridil-prolonged QT interval, decreased J wave
amplitude, and abolished T wave inversion in V2 of
a representative patient are shown in Figure 10. QT-
RR regression lines obtained from automatic analy-
sis of 24-hour Holter ECG recordings revealed that
bepridil increased the QT-RR slope from 0.10 to
0.16 (Figure 11). In 8 idiopathic VF patients, phar-
macological therapy increased the slope of the QT-
RR regression line from 0:11 0:02 to 0:14 0:04
(P < 0.05). Accordingly, QT(1.0) and QT(1.2) be-
came longer after drug therapy [QT(1.0), 0:38
0:02 sec vs. 0:41 0:02 sec (P < 0.01); QT(1.2),
0:40 0:02 sec vs. 0:44 0:02 sec (P < 0.01)].
However, QT(0.6) did not change after drug admin-
istration.
Before drug therapy, the average number of
episodes of VF was 5:5 5:8 (range 1 to 17) during
the observation period of 19:3 17:6 months (range
6 to 60 months) (Table 1). After drug therapy, 6
patients had no episode of VF for 24 to 120 months
(66:0 38:5 months). Two patients had a single
episode of VF in 12- and 96-month follow-ups.
Pharmacological therapy decreased the frequency of
VF episodes in association with prolongation of QT
intervals at slower heart rates. Not only J wave and
ST elevation but also shorter QT intervals at slower
heart rates may represent an electrophysiological
substrate for development of VF episodes in these
speciﬁc idiopathic VF patients.
Safety of Antiarrhythmic Drugs
It is possible that adverse eﬀects counterbalance
the beneﬁts of antiarrhythmic drugs in some patients.
Hence, safe usage is essential for the treatment of
arrhythmia using antiarrhythmic drugs. Physicians
should pay more attention to identifying patients
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Figure 11 QT-RR relationship in a patient with Brugada syndrome before and after pharmacological therapy with bepridil
(from reference 55).
The slope of the QT-RR regression line before drug therapy (control) was lower than that after bepridil therapy. This is the same patient as
shown in Figure 10.
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who may suﬀer from adverse eﬀects of antiarrhyth-
mic drugs.
Adequate evaluation of the QT interval is essential
for safe use of K channel blockers including bepridil.
However, correction of the QT interval by any heart
rate adjustment method may have limitations. We
made a nomogram of the normal QT interval at
various heart rates based on automatic measurements
of 24-hour Holter ECG recordings in 422 healthy
subjects.56) Evaluation of the QT interval without the
correction formula using this nomogram is useful for
QT interval measurement after administration of K
channel blockers. For safe use, the maximum dosage
of bepridil should be limited 200mg/day, and
serum K  4.0mmol/L should be maintained by
administration of renin-angiotensin-aldosterone sys-
tem inhibitors.
Conclusion
Reversal of the remodeled atria in persistent
AF57) and modiﬁcation of the repolarization dynam-
ics in idiopathic VF may become a new target for
pharmacological antiarrhythmic therapy. Although
the current trend in treatment for arrhythmia has
shifted to non-pharmacological therapy, pharmaco-
logical therapy still plays a key role for treatment of
ﬁbrillations.
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